Firms, funds, partners, companies and rounds from sworn filings, firm sites and announcements, kept as a graph with a date and a source on every edge. Facts, inferences and estimates are labelled as such. A fund target is never a close, GAV is never dry powder, and a round size is never an investor’s check.

Companies / Superluminal Medicines, Inc.

Superluminal Medicines, Inc.

Series BWaltham, MABiotechnology
Facts
Year of incorporation
2023sec.gov
Revenue range (Form D)
Decline to Disclosesec.gov
Rounds on record
2
Disclosed raised
$60.0Msum of rounds with a disclosed amount only
Named investors
7
Financing history
2 rounds
  1. Sep 3, 2026
    Series B · $60.0M (disclosed)
    BVF Partners (lead)Insight Venture Partners (participant)Catalio Capital Management, LP (participant)Eli Lilly (participant)Bioeconomy Capital GP, LLC (participant)Perceptive Advisors (participant)NVIDIA (participant)
    Fact Press release wires (Business Wire, PR Newswire, GlobeNewswire public RSS) · “Superluminal Medicines Announces Oversubscribed $60 Million Series B Financing to Advance Lead Program in Rare Genetic Forms of Obesity into the Clinic”
  2. Aug 21, 2024
    Form D equity offering · $20.0M (form d sold) · 12 investors
    Fact SEC EDGAR Form D data sets (quarterly) · “Superluminal Medicines, Inc. filed Form D: $20,041,660 sold of $119,999,984, Biotechnology”
Investors on record
7 edges
People
2 officers, 3 directors
Timeline
2
  1. Sep 3, 2026
    Superluminal Medicines announced Series B of $60,000,000, led by BVF Partners
    Round announced Fact Press release wires (Business Wire, PR Newswire, GlobeNewswire public RSS)
  2. Sep 4, 2024
    Superluminal Medicines, Inc. filed Form D: $20,041,660 sold of $119,999,984, Biotechnology
    Form D filed Fact SEC EDGAR Form D data sets (quarterly)
Evidence
16 observations
Every observation on this company